洛伐他汀对血脂和纤溶活性的影响  

The Effcct of Lovastatin on Lipids and Fibrinolytic Activity

作　　者：刘恒亮[1] 高艳艳[2] 

机构地区：[1]郑州市第五人民医院心内科,450000 [2]河南省沈丘县中医院

出　　处：《中华临床医学卫生杂志》2005年第11期26-28,共3页China Journal of Clinical Medicine Hygiene

摘　　要：目的观察洛伐他汀对高脂血症和／或冠心病患者血脂和组织型纤溶酶原激活剂（tissue type plasminogen activator，t-PA）及其抑制物（plasminogen activator inhibitor-I，PAI-I）活性的影响。方法68例原发性高胆固醇血症患者给予洛伐他汀20mg／d，连续应用8周；观察用药前后TC、TG、LDL-C、HDL-C、apoA-I，apo B和t-PA、PAI-I活性的变化。结果治疗8周后，血TC、TG、LDL-C、apo B和PAI-I的活性品著低于治疗前（P〈0．05），HDL-C、apoA-I显著高于治疗前（P〈0．05）。结论洛伐他汀不仅能降低血脂，而且能改变纤溶活性，对冠心病患者产生有益的作用。Objective To study effects of lovastatin on lipids, tissue type plasminogen activator （t-PA） and plasminogen activator inhibitor-I（PAI-I） in patients with essential hyperlipidemia with or without coronary artery disease（CAD）. Methods 68 cases of essential hyperlipidemia with or witbout CAD were given lovastatin （20mg daily） tot a period of 8 weeks and changes of TC、TG、LDL-C、HDL-C、apoA-I apo B, t-PA and PAI-I were studied. Results At the end of the study, the levels of TC、TG、LDL-C、apo B and PAI-I decreased remarkably （P〈0.05）, the levels of HDL-C and apoA-I increased remarkably （P〈0.05）. Conclusion Lovastatin decrease levels of TC、TG、LDL-C、apo B and PAI-I, increase levels of HDL-C、apoA-I、improve fibrinolytic activity and can produce benefit to patients with CAD.

关 键 词：洛伐他汀 血脂 纤溶活性 高脂血症 冠心病 

分 类 号：R972.6[医药卫生—药品]